IMMUNODIAGNOSTICS  |  IMMUNOMONITORINGImmuQuad Biotech   ·   Contact@ImmuQuad.com

How Seq-MRD works

Patient-specific BCR/TCR rearrangements provide molecular labels that can be identified at high disease burden and followed throughout treatment.

Seq-MRD two-step testing workflow
Two-step testing

Baseline clone identification followed by MRD tracking

1

Clonality identification

A diagnostic or relapse specimen with high disease burden is sequenced to identify dominant disease-associated immune receptor rearrangements—the patient’s molecular tracking markers.

DiagnosisClinical relapseHigh tumor burden
2

MRD tracking

One or more follow-up specimens are tested for the previously identified markers. Analysis also screens for new clonal sequences that may reflect clonal evolution or a new process requiring review.

During therapyPost-treatmentLong-term follow-up
Biological principle

BCR and TCR rearrangements act as molecular labels

V(D)J recombination and junctional nucleotide addition/deletion create highly diverse immune receptor sequences. A lymphoid malignant clone carries a reproducible rearrangement that can be used as a patient-specific tracking target.

  • B-cell malignancies may yield IGH, incomplete IGH, IGK or IGL targets.
  • T-cell malignancies may yield TRB or TRG targets.
  • Multiple loci can be evaluated to increase the opportunity for finding a reliable marker.
Immune receptor clone as a patient-specific molecular marker
Six technical design features

From library construction to clone interpretation

1. Optimized library construction

Synthetic control molecules that resemble complete V–J rearrangements support primer balancing and help reduce multiplex-PCR amplification bias.

2. Internal quantitative reference

An internal reference library supports estimation of the total nucleated-cell equivalent used as the MRD denominator.

3. Multi-locus coverage

TRB, TRG, IGH, incomplete IGH, IGK and IGL are included in the platform’s broader receptor assessment strategy.

4. SHM-aware detection

Assay design addresses somatic hypermutation, which can otherwise reduce detection of B-cell receptor targets.

5. Clone significance assessment

ImmuQuad’s large TCR/BCR reference database and a Uniqueness Index contribute to assessment of significant clonal sequences.

6. Deep sequence tracking

With sufficient sample input, sequencing depth can support detection approaching one target receptor sequence per million receptor templates.

Reporting framework

Information that can be incorporated into a Seq-MRD report

Report componentPurpose
Baseline clonotype profileDocuments disease-associated sequence markers identified in the high-burden sample.
Marker-specific quantitative resultReports the detected level of each tracked target using the assay’s quantitative denominator.
Sample and quality metricsProvides context on input, sequencing and analysis quality needed for interpretation.
Emerging clone observationsFlags newly prominent rearrangements that may require correlation with diagnosis, treatment and other tests.
Longitudinal trendPlaces the current result alongside previous time points to show kinetics.

Exact report fields and interpretation language depend on the selected product configuration and local laboratory procedures.

Discuss a Seq-MRD project with ImmuQuad

Clinical testing, translational research, clinical trials and biopharma collaborations.

Contact our team